Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada (vol 25, pg 32, 2018)

被引：0
|
作者：
Chua, A.
Perrin, A.
Ricci, J. F.
Neary, M. P.
Thabane, M.
机构：
来源：
CURRENT ONCOLOGY | 2018年 / 25卷 / 04期
关键词：
D O I：
10.3747/co.25.4233
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E354 / E355
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada
    Chua, A.
    Perrin, A.
    Ricci, J. F.
    Neary, M. P.
    Thabane, M.
    CURRENT ONCOLOGY, 2018, 25 (01) : 32 - 40
  • [2] COST-EFFECTIVENESS OF EVEROLIMUS FOR PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS OF THE GASTROINTESTINAL (GI) OR LUNG ORIGIN-A CANADIAN SOCIETAL HEALTH CARE SYSTEM PERSPECTIVE
    Perrin, A.
    Chua, A.
    Ricci, J.
    Neary, M.
    Thabane, M.
    VALUE IN HEALTH, 2016, 19 (07) : A734 - A734
  • [3] Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours
    Daniel M. Huse
    Margaret von Mehren
    Gregory Lenhart
    Heikki Joensuu
    Charles Blanke
    Weiwei Feng
    Stan Finkelstein
    George Demetri
    Clinical Drug Investigation, 2007, 27 : 85 - 93
  • [4] Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours
    Huse, Daniel M.
    von Mehren, Margaret
    Lenhart, Gregory
    Joensuu, Heikki
    Blanke, Charles
    Feng, Weiwei
    Finkelstein, Stan
    Demetri, George
    CLINICAL DRUG INVESTIGATION, 2007, 27 (02) : 85 - 93
  • [5] The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada
    Duong, M.
    Wright, E.
    Yin, L.
    Martin-Nunez, I.
    Ghatage, P.
    Fung-Kee-Fung, M.
    CURRENT ONCOLOGY, 2016, 23 (05) : E461 - E467
  • [6] Cost-effectiveness of regorafenib in the treatment of advanced hepatocellular carcinoma in Canada
    Hussain, Salman
    Singh, Ambrish
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 382 - 382
  • [7] Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
    Mujica-Mota, Ruben
    Varley-Campbell, Jo
    Tikhonova, Irina
    Cooper, Chris
    Griffin, Ed
    Haasova, Marcela
    Peters, Jaime
    Lucherini, Stefano
    Talens-Bou, Juan
    Long, Linda
    Sherriff, David
    Napier, Mark
    Ramage, John
    Hoyle, Martin
    HEALTH TECHNOLOGY ASSESSMENT, 2018, 22 (49) : 1 - +
  • [8] COST-EFFECTIVENESS OF TREATING ADVANCED PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMOR PATIENTS WITH EVEROLIMUS VERSUS SUNITINIB IN SWEDEN
    Perrin, A.
    Park, J.
    Jacob, J.
    Welin, S.
    VALUE IN HEALTH, 2015, 18 (03) : A204 - A204
  • [9] Cost-effectiveness of treating patients with advanced progressive pancreatic neuroendocrine tumors with everolimus versus sunitinib in the United States
    Chulikavit, Maruit
    Casciano, Roman
    Perrin, Allison
    Liu, Zhimei
    Wang, Xufang
    Babigumira, Joseph
    Grzegorzewski, Kris
    Garrison, Louis P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic
    Rose, Darya B.
    Nellesen, Dave
    Neary, Maureen P.
    Cai, Beilei
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (04) : 395 - 404
12345